China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the enrollment of the first subject in a prospective, subject-controlled, multi-center Phase III clinical study. The study aims to assess the additional detection rate and safety of Hexvix, a bladder cancer diagnosis and postoperative detection product, in non-muscle invasive bladder cancer (NMIBC) (carcinoma in situ, Ta, T1) when used in combination with blue light cystoscopy compared to white light cystoscopy.
Hexvix Profile
Hexvix is the world’s only approved agent for assisting in the diagnosis or surgery of bladder cancer. It can effectively improve the detection rate of NMIBC when used in combination with blue light cystoscopy. Hexvix has already been approved in the US, Europe, and China and is included in the global expert consensus guidelines for the management of non-muscle invasive bladder cancer (NMIBC) when used with a blue light cystoscope.
Partnership and Market Expansion
In January of this year, Asieris struck a partnership with Norway-headquartered Photocure ASA (PHO: OSE), securing exclusive regulatory filing and commercialization rights to Hexvix in mainland China and Taiwan. This strategic move underscores Asieris’ commitment to advancing innovative solutions for bladder cancer detection and treatment.-Fineline Info & Tech
